Sequential Immunizations with Rgp120s from Independent Isolates of Human Immunodeficiency Virus Type 1 Induce the Preferential Expansion of Broadly Crossreactive B Cells

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1991 Apr 1

PMID 2007856

Citations 12

Authors

D M Klinman

K W Higgins

J Conover

Affiliations

Soon will be listed here.

Abstract

The gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is a dominant target against which the host's humoral immune response is directed. Unfortunately, gp120 proteins from different isolates of HIV are antigenically distinct, complicating the use of the envelope glycoprotein in vaccines designed to prevent acquired immunodeficiency syndrome. Using an enzyme-linked immunosorbent spot assay (ELISA), BALB/c mice immunized and boosted with recombinant purified gp120 were studied at the single cell level for their humoral immune response to HIV-1 envelope proteins. Approximately 90% of responding B cells produced antibodies reactive with the immunizing form of gp120 but not with gp120s from other strains of HIV. A novel sandwich ELISA was then used to analyze the frequency with which individual in vivo activated B cells produced antibodies that crossreacted with heterologous gp120s. Repeated immunizations with a single gp120 or with a mixture of different gp120s resulted in the activation of primarily mono-specific (noncrossreactive) B cells. In contrast, the sequential immunization of mice with recombinant purified envelope proteins from different strains of HIV (IIIB, SF2, and Zr6) induced the selective expansion of B cells producing highly crossreactive antibodies.

Citing Articles

Enhancement of Neutralization Responses through Sequential Immunization of Stable Env Trimers Based on Consensus Sequences from Select Time Points by Mimicking Natural Infection.

Wan M, Yang X, Sun J, Giorgi E, Ding X, Zhou Y Int J Mol Sci. 2023; 24(16).

PMID: 37628824 PMC: 10454455. DOI: 10.3390/ijms241612642.

IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.

Blasi M, Negri D, LaBranche C, Alam S, Baker E, Brunner E Commun Biol. 2018; 1:134.

PMID: 30272013 PMC: 6125466. DOI: 10.1038/s42003-018-0131-6.

Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.

Verkoczy L Adv Immunol. 2017; 134:235-352.

PMID: 28413022 PMC: 5914178. DOI: 10.1016/bs.ai.2017.01.004.

Progress toward active or passive HIV-1 vaccination.

Escolano A, Dosenovic P, Nussenzweig M J Exp Med. 2016; 214(1):3-16.

PMID: 28003309 PMC: 5206506. DOI: 10.1084/jem.20161765.

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

Escolano A, Steichen J, Dosenovic P, Kulp D, Golijanin J, Sok D Cell. 2016; 166(6):1445-1458.e12.

PMID: 27610569 PMC: 5019122. DOI: 10.1016/j.cell.2016.07.030.

References

Cunningham A, Pilarski L . Generation of antibody diversity. I. Kinetics of production of different antibody specificities during the course of an immune response. Eur J Immunol. 1974; 4(5):319-26. DOI: 10.1002/eji.1830040502. View

Klinman D, Steinberg A . Novel ELISA and ELISA-spot assays used to quantitate B cells and serum antibodies specific for T cell and bromelated mouse red blood cell autoantigens. J Immunol Methods. 1987; 102(2):157-64. DOI: 10.1016/0022-1759(87)90072-x. View

PRINCE H, Kermani-Arab V, Fahey J . Depressed interleukin 2 receptor expression in acquired immune deficiency and lymphadenopathy syndromes. J Immunol. 1984; 133(3):1313-7. View

Dalgleish A, Beverley P, Clapham P, Crawford D, Greaves M, Weiss R . The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312(5996):763-7. DOI: 10.1038/312763a0. View

Ratner L, Gallo R, Wong-Staal F . HTLV-III, LAV, ARV are variants of same AIDS virus. Nature. 1985; 313(6004):636-7. DOI: 10.1038/313636c0. View

Hahn B, Gonda M, Shaw G, Popovic M, Hoxie J, Gallo R . Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A. 1985; 82(14):4813-7. PMC: 390995. DOI: 10.1073/pnas.82.14.4813. View

Arthur L, Pyle S, Nara P, Bess Jr J, Gonda M, Kelliher J . Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A. 1987; 84(23):8583-7. PMC: 299589. DOI: 10.1073/pnas.84.23.8583. View

Ho D, Kaplan J, Rackauskas I, Gurney M . Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science. 1988; 239(4843):1021-3. DOI: 10.1126/science.2830667. View

Palker T, Clark M, Langlois A, Matthews T, Weinhold K, Randall R . Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A. 1988; 85(6):1932-6. PMC: 279895. DOI: 10.1073/pnas.85.6.1932. View

10.

Matthews T, Langlois A, Robey W, Chang N, Gallo R, Fischinger P . Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein. Haematol Blood Transfus. 1987; 31:414-22. DOI: 10.1007/978-3-642-72624-8_89. View

11.

Vujcic L, Shepp D, Klutch M, Wells M, Hendry R, Wittek A . Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J Infect Dis. 1988; 157(5):1047-50. DOI: 10.1093/infdis/157.5.1047. View

12.

Takahashi H, Cohen J, Hosmalin A, Cease K, Houghten R, Cornette J . An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1988; 85(9):3105-9. PMC: 280152. DOI: 10.1073/pnas.85.9.3105. View

13.

Rusche J, Javaherian K, McDanal C, Petro J, Lynn D, Grimaila R . Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A. 1988; 85(9):3198-202. PMC: 280171. DOI: 10.1073/pnas.85.9.3198. View

14.

Goudsmit J, Debouck C, Meloen R, Smit L, Bakker M, Asher D . Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A. 1988; 85(12):4478-82. PMC: 280453. DOI: 10.1073/pnas.85.12.4478. View

15.

Nara P, Robey W, Pyle S, Hatch W, Dunlop N, Bess Jr J . Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol. 1988; 62(8):2622-8. PMC: 253692. DOI: 10.1128/JVI.62.8.2622-2628.1988. View

16.

Robert-Guroff M, Goedert J, Naugle C, Jennings A, Blattner W, Gallo R . Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study. AIDS Res Hum Retroviruses. 1988; 4(5):343-50. DOI: 10.1089/aid.1988.4.343. View

17.

Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J . Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell. 1989; 58(5):901-10. DOI: 10.1016/0092-8674(89)90942-2. View

18.

Haigwood N, Shuster J, Moore G, Lee H, Skiles P, Higgins K . Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses. 1990; 6(7):855-69. DOI: 10.1089/aid.1990.6.855. View

19.

Lane H, Fauci A . Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol. 1985; 3:477-500. DOI: 10.1146/annurev.iy.03.040185.002401. View

20.

Starcich B, Hahn B, Shaw G, McNeely P, Modrow S, Wolf H . Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986; 45(5):637-48. DOI: 10.1016/0092-8674(86)90778-6. View